Patents Assigned to Hoffmann-La Roche Inc.
  • Publication number: 20200199214
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • Publication number: 20200199234
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
  • Publication number: 20200199155
    Abstract: Compounds of formula (I) wherein R1, R2, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Daniel HUNZIKER, Jerome HERT, Holger KUEHNE, Patrizio MATTEI, Markus RUDOLPH
  • Publication number: 20200199690
    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.
    Type: Application
    Filed: March 10, 2020
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anton BELOUSOV, Giampaolo Bianchini, Luca GIANNI, Marlene THOMAS
  • Publication number: 20200199215
    Abstract: The present invention relates to the combination therapy of an antibodies that binds to human angiopoietin 2 (ANG-2) with a CD40 agonist.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Markus Thomas, Alfred Zippelius, Philipp Mueller
  • Publication number: 20200199230
    Abstract: The present invention relates to the treatment of cancer, in particular to the prevention of adverse effects caused by the administration of CD3 antibodies in the course of said treatment.
    Type: Application
    Filed: November 22, 2019
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jose Saro, Said Bouseida, Federico Sandoval Morales
  • Patent number: 10689339
    Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 23, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Wolfgang Haap, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters
  • Publication number: 20200190206
    Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: June 19, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia FERRARA KOLLER, Christina CLAUS, Christian KLEIN, Pablo UMAÑA, Wei XU
  • Publication number: 20200190207
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 30, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Harald DUERR, Christian KLEIN, Pablo UMANA, Alexander BUJOTZEK, Joerg ZIELONKA, Christine TRUMPFHELLER, Moritz RAPP, Marine LE CLECH
  • Publication number: 20200188526
    Abstract: The invention provides compositions and methods for treating cancer, the method comprising administering an IL-2 immunoconjugate, a CD40 agonist and optionally a PD-1 axis binding antagonist.
    Type: Application
    Filed: October 8, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Valeria G. NICOLINI, Pablo UMAÑA
  • Publication number: 20200190553
    Abstract: A deep eutectic solvent consisting of (2-hydroxyethyl) trimethyl ammonium chloride and dithiothreitol in a molar ratio of from 1:2 to 1:3 and from 0% to 10% co-solvent, and methods of enzymatic production of polypeptides using the deep eutectic solvent.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mara Boenitz-Dulat, Martin Schatte
  • Publication number: 20200190212
    Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 30, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas HOFER, Maximiliane KOENIG, Ekkehard MOESSNER, Jens NIEWOEHNER, Tina WEINZIERL, Laurent LARIVIERE
  • Publication number: 20200188296
    Abstract: Disclosed herein is a new use of liquid pharmaceutical preparations comprising immune agonistic antibodies, resulting in improved tolerability/adverse event profile while at least maintaining the same level of biological activity of said immune agonist.
    Type: Application
    Filed: November 27, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Gonzalo Acuña, Emily Rana Corse, Jehad Charo, Martin Lechmann, Martin Stern
  • Patent number: 10684227
    Abstract: A method for the detection of binding affinities comprises providing a device having a planar waveguide (2) arranged on a substrate (3) and an optical coupler (4). Coherent light (1) of a predetermined wavelength is coupled into the planar waveguide (2) such that the coherent light propagates along the planar waveguide (2), with an evanescent field (6) of the coherent light propagating along an outer surface (5) of the planar waveguide (2). Target samples (8) attached to binding sites (7) are arranged along a plurality of predetermined lines (9) on the outer surface (5) of the planar waveguide (2). At a predetermined detection location, light of the evanescent field which is scattered by target samples (8) bound to binding sites (7) arranged along the predetermined lines (9) is detected.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: June 16, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Christof Fattinger
  • Patent number: 10683299
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: June 16, 2020
    Assignee: HOFFMANN LA ROCHE INC.
    Inventors: Xingchun Han, Xianfeng Lin, Hong Shen, Taishan Hu, Zhisen Zhang
  • Patent number: 10683368
    Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein a) the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and b) the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and c) the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprisi
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: June 16, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ekkehard Moessner, Tilman Schlothauer
  • Patent number: 10683329
    Abstract: Provided herein are peptides having dual-site BACE1 inhibitory activity, useful for the treatment of, for example Alzheimer's disease and diabetes. One such peptide is a dual-site BACE1 inhibitor, or a pharmaceutically acceptable salt thereof, binding to both an enzymatic active site and an catalytic domain of the BACE enzyme, and an exosite inhibitory part is connected to an active-site inhibitory part of the dual site BACE1 inhibitor by a linker.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: June 16, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Per-Ola Freskgard, Eric A. Kitas
  • Publication number: 20200181669
    Abstract: Herein is reported a method for the production of an immunoglobulin comprising the following steps: a) providing a eukaryotic cell comprising a nucleic acid encoding the immunoglobulin, b) cultivating the eukaryotic cell in a cultivation medium wherein the amount of glucose available in the cultivation medium per time unit is kept constant and limited to less than 80% of the amount that could maximally be utilized by the cells in the cultivation medium per time unit, and c) recovering the immunoglobulin from the culture.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 11, 2020
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Reinhard Franze, Chikashi Hirashima, Thomas Link, Yoshinori Takagi, Shinya Takuma, Yuriko Tsuda
  • Publication number: 20200181156
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R3 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 11, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Buyu Kou, Haixia Liu, Zhisen Zhang, Zheng Zhou
  • Publication number: 20200182861
    Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into vascular bed cells. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into vascular bed cells based on linked steps of chemically defined medium inductions.
    Type: Application
    Filed: September 5, 2019
    Publication date: June 11, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Klaus Christensen, Martin Graf, Roberto Iacone, Christoph Patsch, Eva Christina Thoma